Ocular Therapeutix (NASDAQ:OCUL) Stock Gets Price Target Boost from HC Wainwright

Ocular Therapeutix (NASDAQ:OCUL) had its price objective hoisted by stock analysts at HC Wainwright from $25.00 to $28.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright‘s target price points to a potential upside of 308.76% from the company’s current price.

Several other research firms also recently issued reports on OCUL. Wall Street Zen raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Chardan Capital reissued a “buy” rating and issued a $23.00 price objective on shares of Ocular Therapeutix in a research note on Friday, October 2nd. Needham & Company LLC restated a “buy” rating and issued a $18.00 price objective on shares of Ocular Therapeutix in a report on Monday, October 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, October 15th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $23.83.

Ocular Therapeutix Trading Up 3.9%

Shares of NASDAQ OCUL opened at $6.85 on Tuesday. The company has a 50 day simple moving average of $8.33 and a 200 day simple moving average of $9.00. Ocular Therapeutix has a 1 year low of $6.00 and a 1 year high of $16.44. The company has a current ratio of 13.10, a quick ratio of 13.03 and a debt-to-equity ratio of 0.14.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.06). Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%. The business had revenue of $12.87 million for the quarter, compared to analyst estimates of $14.27 million. During the same quarter in the prior year, the business earned ($0.38) earnings per share. The firm’s quarterly revenue was down 11.5% on a year-over-year basis. Equities research analysts anticipate that Ocular Therapeutix will post -1.47 EPS for the current fiscal year.

Insider Activity

In other news, insider Pravin Dugel sold 21,649 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $10.77, for a total value of $233,159.73. Following the transaction, the insider owned 2,525,429 shares in the company, valued at approximately $27,198,870.33. The trade was a 0.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Namrata Saroj sold 35,370 shares of the company’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $6.55, for a total transaction of $231,673.50. Following the completion of the sale, the insider directly owned 220,522 shares in the company, valued at approximately $1,444,419.10. This represents a 13.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 98,090 shares of company stock worth $787,920. 3.10% of the stock is owned by insiders.

Institutional Trading of Ocular Therapeutix

A number of institutional investors have recently bought and sold shares of the company. CenterBook Partners LP acquired a new stake in Ocular Therapeutix during the 3rd quarter worth about $233,000. Kraematon Investment Advisors Inc. boosted its position in shares of Ocular Therapeutix by 6.9% during the 3rd quarter. Kraematon Investment Advisors Inc. now owns 117,517 shares of the biopharmaceutical company’s stock valued at $901,000 after purchasing an additional 7,550 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in shares of Ocular Therapeutix by 8.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 20,992 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 1,575 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Ocular Therapeutix during the third quarter worth approximately $86,000. Finally, Profund Advisors LLC grew its stake in Ocular Therapeutix by 316.0% during the third quarter. Profund Advisors LLC now owns 138,128 shares of the biopharmaceutical company’s stock worth $1,059,000 after purchasing an additional 104,927 shares during the period. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix News Roundup

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Ocular Therapeutix plans to submit an NDA for AXPAXLI in the fourth quarter of 2026. Its $530.6 million cash balance is expected to fund operations into 2028, reducing near-term financing concerns. Article: AXPAXLI filing plan and cash runway
• Neutral Sentiment: Insider Namrata Saroj sold 35,370 shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. The stated reason makes the transaction less indicative of a discretionary view on OCUL. SEC insider transaction filing
• Neutral Sentiment: The company appointed Riad Sherif to its board of directors, a governance change with no immediate, clear financial impact. Article: Board appointment
• Negative Sentiment: Third-quarter results missed expectations: the company reported a $0.42-per-share loss versus the expected $0.36 loss, while revenue of $12.87 million fell short of the $14.27 million consensus and declined 11.5% year over year. Article: Third-quarter earnings miss
• Negative Sentiment: Reports also pointed to costs of advancing AXPAXLI and declining DEXTENZA sales, highlighting pressure on near-term operating performance. Article: Pipeline costs and DEXTENZA sales

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time.

Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.

The company was founded in 2006 and serves the U.S.